跳至主要内容
临床试验/NL-OMON48560
NL-OMON48560招募中2 期

PRostatE Cancer MRI guided focal SalvagE high-dose-rate brachytherapy - PRECISE

niversitair Medisch Centrum Utrecht0 个研究点目标入组 88 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
88

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age >=18 years;
  • - Recurrence >=2 years after primary radiotherapy treatment (low-dose-rate
  • brachytherapy of external beam radiation therapy);
  • - Prostate Specific Antigen (PSA) at time of salvage <=20 ng/ml;
  • - Prostate Specific Antigen (PSA) doubling time >=9 months;
  • - Stage <=T3b tumor (extra prostatic extension into the seminal vesicle(s));
  • - Acceptable toxicity of primary radiation treatment (International Prostate
  • Symptom Score (IPSS)<15);
  • - Concordance between PSMA-PET/CT and mp-MRI;
  • - Tumor location technically feasible for brachytherapy;
  • - Karnofsky score >=70;
  • - Written informed consent;
  • - Fit for spinal anesthesia.

排除标准

  • - Distant metastases;
  • - Previous pelvic radiotherapy for another malignancy;
  • - Prior prostate treatment(s) like a recent transurethral resection of the
  • prostate (TURP) (<6 months before focal salvage HDR treatment), HIFU or
  • cryosurgery, except for radiotherapy;
  • - Contraindications for MRI;
  • - Severe toxicity from primary radiation treatment (IPSS >15);
  • - Anticoagulant administration continuously required, except for platelet
  • aggregation inhibitors (for example Ascal/Persantin).

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验